Table 5.
Clinical and laboratory results of patients by hypertension at diagnosis
| Clinical parameters | Total cohort HTN (n = 84) | Total cohort Nn HTN (n = 78) | P value | IC-MPGN HTN (n = 24) | IC-MPGN no HTN (n = 18) | P value | C3G HTN (n = 19) | C3G no HTN (n = 23) | P value |
|---|---|---|---|---|---|---|---|---|---|
| eGFR at diagnosis (ml/min per 1.73 m2) | 63.9 (53.5–74.2) | 84.0 (69.8–98.1) | 0.0204a | 75.5 (60.2–90.8) | 80.0 (52.8–107.3) | NS (0.7377) | 67.3 (43.8–90.8) | 99.6 (79.0–120.3) | 0.036a |
| eGFR at last follow-up (ml/min per 1.73 m2) | 82.4 (71.2– 93.7) | 103.9 (92.6–115.2) | 0.0088a | 87.6 (71.5–103.6) | 107.2 (95.0–119.4) | NS (0.0972) | 110.4 (86.4–134.3) | 100.4 (78.4–122.3) | NS (0.5231) |
| Delta eGFR (ml/min per 1.73 m2) | 29.8 (9.9–49.7) | 20.3 (5.5–35.1) | NS (0.4452) | 10.0 (−10.4to −30.4) | 27.0 (−7.5 to 61.4) | NS (0.1876) | 44.3 (1.0–87.6) | 14.4 (−13.2 to 42.1) | NS (0.2275) |
| C3 at diagnosis (g/l) | 0.40 (0.32–0.29) | 0.46 (0.34–0.57) | NS (0.4521) | 0.31 (0.19–0.42) | 0.49 (0.15–0.83) | NS (0.1595) | 0.24 (0.12–0.36) | 0.51 (0.27–0.75) | NS (0.0742) |
| C3 at last follow-up (g/l) | 0.66 (0.54–0.79) | 0.71 (0.56–0.85) | NS (0.6278) | 0.52 (0.27–0.76) | 0.35 (0.001–0.70) | NS (0.4119) | 0.73 (0.50–0.96) | 0.78 (0.50–1.1) | NS (0.7956) |
| Urine protein/creatinine ratio at diagnosis (mg/mmol) | 437.8 (225.2–650.4) | 360.4 (132.4–588.3) | NS (0.6192) | 433.8 (220.7–646.8) | 499.5 (−277.9 to 1277) | NS (0.7973) | 504.0 (98.6–909.3) | 229.3 (40.0–418.6) | NS (0.1797) |
| Urine protein/creatinine ratio at last follow-up (mg/mmol) | 210.4 (15.8–405.0) | 232.4 (82.9–381.8) | NS (0.8597) | 171.2 (51.0–291.4) | 244.7 (−84.3 to 573.7) | NS (0.5848) | 82.9 (36.4–129.3) | 143.6 (59.1–228.2) | NS (0.2173) |
| On antihypertensives at diagnosis | 71.6% | 23.1% | 0.0012a | 75.0% | 33.3% | NS (0.2010) | 75.0% | 66.7% | NS (>0.9999) |
| On antihypertensives at last follow-up | 71.1% | 59.0% | NS (0.1363) | 87.5% | 50.0% | 0.0144a | 68.4% | 78.3% | NS (0.5038) |
| Antihypertensives per patient at diagnosis | 2.4 (2.1–2.7) | 1.3 (0.8–1.8) | 0.0004a | 2.5 (1.7–3.2) | 1.4 (0.25–2.6) | NS (0.1455) | 2.3 (1.7–3.0) | 0.6 (−0.2 to 1.4) | 0.0011a |
| Antihypertensives per patient at last follow-up | 1.9 (1.6–2.3) | 1.4 (1.1–1.7) | 0.0166a | 1.9 (1.5–2.4) | 1.5 (0.2–2.7) | NS (0.3516) | 1.4 (0.7–2.2) | 1.2 (0.7–1.6) | NS (0.4902) |
C3, serum C3 level (reference range 0.83–1.52 g/l); Cr, serum creatinine; eGFR, estimated glomerular filtration rate based on the bedside Schwartz formula; IC-MPGN, immune-complex membranoproliferative glomerulonephritis; NS, not significant.
Numeric data shown as the mean with 95% confidence interval.
a
Statistically significant.